赢8娱乐糖果配对游戏-官方网站[welcome]


+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Transurethral resection with perioperative instillation of interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: A prospective randomized multicenter study-Finnbladder III



Transurethral resection with perioperative instillation of interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: A prospective randomized multicenter study-Finnbladder III



Journal of Urology 161(4): 1133-1136



Purpose: We evaluated the efficacy of single dose of interferon or epirubicin administered immediately after transurethral resection compared with transurethral resection only on the recurrence of primary (not recurrent) superficial bladder cancer. Materials and Methods: A total of 283 patients with stages Ta to T1 primary superficial, grades 1 to 3 bladder cancer was randomized into study groups 1-transurethral resection only, 2-transurethral resection plus 50 million units interferon-alpha2b and 3-transurethral resection plus 100 mg. epirubicin. Eligible for final analysis were 200 patients, including 66 in group 1, 66 in group 2 and 68 in group 3. Patients were followed with cystoscopy every 3 months for 2 years or until the initial recurrence. Results: Group 3 had the most favorable outcome, since 45 of the 68 patients (66%) were without recurrence after 2 years compared to 24 of the 66 (37%) in group 2 and 26 of the 66 (40%) in group 1 (log rank test p <0.001). Side effects were mostly mild and transient, and no differences were found among the groups. Conclusions: A single 100 mg. dose of epirubicin given intravesically immediately after transurethral resection is safe, and significantly decreases the recurrence of primary superficial bladder cancer. A 50 million unit dose of interferon-alpha2b is well tolerated but it has no effect on recurrence as a single dose. The long-term effect of this treatment remains to be studied.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011589678

Download citation: RISBibTeXText

PMID: 10081854

DOI: 10.1016/s0022-5347(01)61609-4


Related references

Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results. Journal of Urology 168(3): 981-985, 2002

Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - Finnbladder III long-term results. International Braz J Urol 28(5): 489-490, 2002

Perioperative Single Dose Instillation of Epirubicin or Interferon- After Transurethral Resection for The Prophylaxis of Primary Superficial Bladder Cancer Recurrence: A Prospective Randomized Multicenter StudyFinnbladder Iii Long-Term Results. The Journal of Urology 168(3): 981-985, 2002

Randomized prospective study comparing long-term intravesical instillation of BCG after transurethral resection and transurethral resection alone in patients with superficial bladder cancer. Journal of Urology 161(4 Suppl. ): 284, 1999

Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study. Hinyokika Kiyo. Acta Urologica Japonica 46(5): 301-306, 2000

Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer--a prospective, controlled three-armed trial. Project Group Bochum--Interferon and Superficial Bladder Cancer. Anti-Cancer Drugs 3(Suppl. 1): 33-37, 1992

Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. Urologia Internationalis 72(4): 284-291, 2004

Epirubicin vs BCG as prophylaxis in superficial bladder cancer A prospective randomized multicenter phase III in trial. Journal of Urology 155(5 Suppl. ): 663A, 1996

Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma. Zhonghua Wai Ke Za Zhi 40(2): 112-115, 2002

Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World Journal of Urology 28(4): 413-418, 2010

Interferon alpha 2b instillation prophylaxis in superficial bladder cancer a prospective controlled three armed trial. Anti-Cancer Drugs 3(Suppl. 1): 33-37, 1992

Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer. Ai Zheng 23(7): 839-841, 2004

Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study. Chinese Medical Journal 126(15): 2805-2809, 2013

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Journal of Urology 156(3): 962-966, 1996

Early intravesical epirubicin instillation after transurethral resection for non-muscle invasive bladder cancer is inefficient for recurrent tumours. European Urology Suppl.s 7(3): 177, 2008





赢8娱乐糖果配对游戏